Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum

Journal of Cellular Physiology

Volumn 202, Issue 3, 2005, Pages 635-641

  Liang, Xing Jie ^a   Shen, Ding Wu ^a   Chen, Kevin G ^a   Wincovitch, Stephen M ^a   Garfield, Susan H ^a   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CISPLATIN; CISPLATIN COMPLEX BINDING PROTEIN; DRUG BINDING PROTEIN; IODIXANOL; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL CULTURE; CELL MEMBRANE; CELL TRANSPORT; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CYTOPLASM; DENSITY GRADIENT CENTRIFUGATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRAFFIC; FLOW CYTOMETRY; GOLGI COMPLEX; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN PROCESSING; STAINING; TRANSPORT VESICLE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL FRACTIONATION; CISPLATIN; CONTRAST MEDIA; DRUG RESISTANCE, NEOPLASM; FLUORESCENT DYES; GOLGI APPARATUS; HUMANS; KB CELLS; MICROSCOPY, FLUORESCENCE; PLATINUM; TRIIODOBENZOIC ACIDS;

ALEXA;

EID: 12944288133     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20253     Document Type: Article

References (29)

1. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM. 1985. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11:117-126.
2. Chauhan SS, Liang XJ, Su AW, Pai-Panandiker A, Shen DW, Hanover JA, Gottesman MM. 2003. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer 88:1327-1334.
3. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC. 1995. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11:1217-1228.
4. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
5. Ilinski P, Lai B, Cai Z, Yun W, Legnini D, Talarico T, Cholewa M, Webster LK, Deacon GB, Rainone S, Phillips DR, Stampfl AP. 2003. The direct mapping of the uptake of platinum anticancer agents in individual human ovarian adenocarcinoma cells using a hard X-ray microprobe. Cancer Res 63:1776-1779.
6. Ishida S, Lee J, Thiele DJ, Herskowitz I. 2002. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302.
7. Johnson SW, Laub PB, Beesley JS, Ozolas RF, Hamilton TC. 1997. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856.
8. Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. 2003. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:466-473.
9. Kelland LR. 1993. New platinum antitumor complexes. Crit Rev Oncol Hematol 15:191-219.
10. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. 1997. Analysis of expression of cMOAT(MRP2), MRP3, MRP4, MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537-3547.
11. Kruh GD. 2003. Lustrous insights into cisplatin accumulation: Copper transporters. Clin Cancer Res 9:5807-5809.
12. Lee P, Gates M, Chang CS, Kirk RG. 1996. X-ray microanalysis and mapping: Measuring uptake and intracellular distribution of labeled molecules. Chin J Physiol 39:205-210.
13. Liang XJ, Shen DW, Garfield SH, Gottesman MM. 2003. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res 63:5909-5916.
14. Liang XJ, Yin JJ, Zhou JW, Wang PC, Taylor B, Cardarelli C, Kozar M, Forte R, Aszalos A, Gottesman MM. 2004. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Exp Cell Res 293:283-291.
15. Lippard SJ, Hoeschele JD. 1979. Binding of cis- and trans-dichloro diammine-platinum (II) to the nucleosome core. Proc Natl Acad Sci USA 76:6091-6095.
16. Nishikawa K, Newman RA, Murray L, Khokhar AH, Rosenblum MG. 1990. Detection of cellular platinum using the monoclonal antibody 1C1. Mol Biother 2:235-241.
17. Ortega R, Moretto P, Fajac A, Benard J, Llabador Y, Simonoff M. 1996. Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. Cell Mol Biol 42:77-88.
18. Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, Apostoli P, Lombardi L, Beggiolin G, Piazzoni L, Zunino F. 2003. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer 105:617-624.
19. Reedijk J, Teuben JM. 1999. Platinum-sulfur interactions involved in antitumour drugs, rescue agents and biomolecules. In: Lippert B, editor. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Basel, Switzerland: Wiley-VCH. pp 339-362.
20. Richon VM, Schulte N, Eastman A. 1987. Multiple mechanisms of resistance to cisdiamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res 47:2056-2061.
21. Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, Howell SB. 2004. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53:239-246.
22. Samimi G, Varki NM, Vilczynski S, Safaei R, Alberts DS, Howell SB. 2003. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 9:5853-5859.
23. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. 1995. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: Cross-resistance and protein changes. Br J Cancer 71:676-683.
24. Shen DW, Pastan I, Gottesman MM. 1998. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 58:268-275.
25. Shen DW, Goldenberg S, Pastan I, Gottesman MM. 2000. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 183:108-116.
26. Siddik ZH. 2003. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279.
27. Siddik ZH, Hagopian GS, Thai G, Tomisaki S, Toyomasu T, Khokhar AR. 1999. Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem 77:65-70.
28. Wang D, Hara R, Singh G, Sancar A, Lippard SJ. 2003. Nucleotide excision repair from site-specifically platinum-modified nucleosomes. Biochemistry 42:6747-6753.
29. Yoon SJ, Park I, Kwak C, Lee E. 2003. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells. Oncol Rep 10:1363-1367.